Sunday, January 3, 2010

CoQ10 deficiency

Send an Email for free membership
  >>>>> Help ME Circle <<<<
>>>>   19 December 2009    <<<<
Editorship :
mail scanned by Comodo I. Security


Neuro Endocrinol Lett.;30(4).

Coenzyme Q10 deficiency in myalgic
encephalomyelitis / chronic fatigue
syndrome (ME/CFS) is related to fatigue,
autonomic and neurocognitive symptoms
and is another risk factor explaining the
early mortality in ME/CFS due to cardi.

Maes M, Mihaylova I, Kubera M, Uytterhoeven M,
Vrydags N, Bosmans E.

Maes Clinics, Antwerp, Belgium.

Myalgic encephalomyelitis / chronic fatigue syndrome
(ME/CFS) is a medical illness characterized by
disorders in inflammatory and oxidative and
nitrosative (IO&NS) pathways.

This paper examines the role of Coenzyme Q10
(CoQ10), a mitochondrial nutrient which acts as an
essential cofactor for the production of ATP in
mitochondria and which displays significant
antioxidant activities.

Plasma CoQ10 has been assayed in 58 patients with
ME/CFS and in 22 normal controls; the relationships
between CoQ10 and the severity of ME/CFS as
measured by means of the FibroFatigue (FF) scale
were measured.

Plasma CoQ10 was significantly (p=0.00001) lower in
ME/CFS patients than in normal controls. Up to
44.8% of patients with ME/CFS had values beneath
the lowest plasma CoQ10 value detected in the
normal controls, i.e. 490 mug/L.

In ME/CFS, there were significant and inverse
relationships between CoQ10 and the total score on
the FF scale, fatigue and autonomic symptoms.

Patients with very low CoQ10 (<390 mug/L) suffered
significantly more from concentration and memory
disturbances. The results show that lowered levels of
CoQ10 play a role in the pathophysiology of ME/CFS
and that symptoms, such as fatigue, and autonomic
and neurocognitive symptoms may be caused by
CoQ10 depletion.

Our results suggest that patients with ME/CFS would
benefit from CoQ10 supplementation in order to
normalize the low CoQ10 syndrome and the IO&NS

The findings that lower CoQ10 is an independent
predictor of chronic heart failure (CHF) and mortality
due to CHF may explain previous reports that the
mean age of ME/CFS patients dying from CHF is 25
years younger than the age of those dying from CHF
in the general population.

Since statins significantly decrease plasma CoQ10,
ME/CFS should be regarded as a relative
contraindication for treatment with statins without
CoQ10 supplementation.

PMID: 20010505 [PubMed - as supplied by publisher]

No comments: